The availability of targeted therapies in kidney cancer has greatly increased su...

Dr. Motzer Analyzes Overall Survival in the TIVO-1 Study

www.onclive.com

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.

Source: http://www.facebook.com/OncLive/posts/212043682269514

camille grammer us supreme court breaking dawn part 2 trailer mississippi state chris carpenter chris carpenter dick cheney